These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25530452)

  • 1. Dose-dependent pharmacokinetics and brain penetration of rufinamide following intravenous and oral administration to rats.
    Gáll Z; Vancea S; Szilágyi T; Gáll O; Kolcsár M
    Eur J Pharm Sci; 2015 Feb; 68():106-13. PubMed ID: 25530452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
    Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of oral rufinamide in dogs.
    Wright HM; Chen AV; Martinez SE; Davies NM
    J Vet Pharmacol Ther; 2012 Dec; 35(6):529-33. PubMed ID: 22132708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview.
    Wier HA; Cerna A; So TY
    Paediatr Drugs; 2011 Apr; 13(2):97-106. PubMed ID: 21351809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models.
    Fortuna A; Alves G; Soares-da-Silva P; Falcão A
    Epilepsy Res; 2013 Nov; 107(1-2):37-50. PubMed ID: 24050973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats.
    Wang C; Quan LH; Guo Y; Liu CY; Liao YH
    Int J Pharm; 2007 Jun; 337(1-2):155-60. PubMed ID: 17267150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study.
    Arzimanoglou A; Ferreira JA; Satlin A; Mendes S; Williams B; Critchley D; Schuck E; Hussein Z; Kumar D; Dhadda S; Bibbiani F
    Eur J Paediatr Neurol; 2016 May; 20(3):393-402. PubMed ID: 26805435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, phase I, 3-way crossover study to examine the effects of food on the pharmacokinetics of single doses of 400 mg posaconazole oral suspension in healthy male Taiwanese subjects.
    Lin TY; Yang MH; Chang FY
    Ther Drug Monit; 2013 Apr; 35(2):223-7. PubMed ID: 23503449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs.
    Bimazubute M; Cambier C; Baert K; Vanbelle S; Chiap P; Gustin P
    J Vet Pharmacol Ther; 2011 Apr; 34(2):176-83. PubMed ID: 21395609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
    Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
    Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic properties of bifenthrin in the rat following multiple routes of exposure.
    Gammon D; Liu Z; Chandrasekaran A; ElNaggar S
    Pest Manag Sci; 2015 Jun; 71(6):835-41. PubMed ID: 25404011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic study of salvianolic acid A in beagle dog after oral administration by a liquid chromatography-mass spectrometry method: a study on bioavailability and dose proportionality.
    Sun J; Zhang L; Song J; Tian S; Huang C; Feng Z; Lv Y; Du G
    J Ethnopharmacol; 2013 Jul; 148(2):617-23. PubMed ID: 23707334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats.
    Koo TS; Kim SJ; Ha DJ; Baek M; Moon H
    Arch Pharm Res; 2011 Dec; 34(12):2059-64. PubMed ID: 22210031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel bioanalytical method for the quantification of rufinamide in mouse plasma and tissues using HPLC-UV: A tool to support pharmacokinetic studies.
    Meirinho S; Rodrigues M; Fortuna A; Falcão A; Alves G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Aug; 1124():340-348. PubMed ID: 31279290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics of single doses of doxylamine succinate following intranasal, oral and intravenous administration in rats.
    Pelser A; Müller DG; du Plessis J; du Preez JL; Goosen C
    Biopharm Drug Dispos; 2002 Sep; 23(6):239-44. PubMed ID: 12214324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of voriconazole after single dose intravenous and oral administration to alpacas.
    Chan HM; Duran SH; Walz PH; Ravis WR
    J Vet Pharmacol Ther; 2009 Jun; 32(3):235-40. PubMed ID: 19646087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation.
    Marchand M; Fuseau E; Critchley DJ
    J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):99-118. PubMed ID: 20084538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
    Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
    Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.